Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.
Zarnie Lwin, MBBS, FRACP, an associate professor, senior staff specialist, and medical oncologist, Cancer Care Services at Royal Brisbane and Women’s Hospital of the University of Queensland, Australia, discusses patient selection, including those with colorectal cancer (CRC), for the phase 2 LEAP-005 study.
Patients were selected for the trial based on both their tumor type and prior lines of therapy, Lwin explains. The trial enrolled patients with several tumor types, including CRC, biliary tract cancer, and gastric cancer, glioblastoma, ovarian cancer, and triple-negative breast cancer; all had received prior standard therapies. Beyond the standard approaches, is difficult to identify efficacious treatments across these tumor types, Lwin adds.
Both tumor types and lines of treatment were matched; all disease types included were ones that need improved treatment protocols, Lwin says. This served as the rationale for examining combination regimens across several tumor types, concludes Lwin.